Gilead Sciences, Inc. (NASDAQ:GILD) stock has been caught in a funk. I have expressed my views on this investment on multiple occasions, and each time, I have come to the same bearish conclusion about Gilead stock. The purpose of …
Given the competitive threats, Baird dismissed Gilead's move into oncology as "incrementally negative" for the stock. Mizuho Securities did a quick straw poll of investors and concluded that "60% of respondents believe Gilead overpaid …
NWI1mon
While biotech and healthcare stocks have underperformed the broader market all year, Gilead stands out for its low forward price-to-earnings ratio, which is widely used by investors to value stocks. The stock closed at $89.53 on …
Gilead Sciences Inc. (NASDAQ: GILD) has become the largest biotech now. The company has run into controversy of late over the pricing of its hepatitis C drug, but it has had controversy over drug pricing in the past as well. Now we have …
Gilead Sciences Inc. GILD, +1.29% shares sank 3.5% after the bell on Tuesday after the company put out disappointing 2017 sales guidance. Fourth-quarter earnings fell to $3.1 billion, or $2.34 per share, from $4.7 billion, or $3.18 per …
It's been a less-than-stellar year for biotech blue chip Gilead Sciences (NASDAQ: GILD). The company's stock has been mired in a pretty steady downtrend since June 2015, and, over the trailing 12 months, it's off an unsightly 26%. Mind …
Investors have turned to the pharmaceutical industry for solid dividend stocks for a long time. However, biotechs typically weren't high on the list when it came to dividends. Over the past few years, though, Amgen, Inc. (NASDAQ: AMGN) …
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one high-profile Wall Street pick and putting it …